^
    Back
    Association details:
    Biomarker:EGFR G719X + EGFR S768I
    Cancer:Lung Adenocarcinoma
    Drug:Gilotrif (afatinib) (pan-HER inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Tokai J Exp Clin Med
    Title:

    Successful Treatment of a Patient with Lung Adenocarcinoma Harboring Compound EGFR Gene Mutations, G719X and S768I, with Afatinib

    Published date:
    09/20/2020
    Excerpt:
    ...a 67-year-old man with lung adenocarcinoma (clinical stage IIIA [cT1N2M0]), harboring an uncommon compound mutation, G719X and S768I...Treatment with afatinib (40 mg/day) produced a partial response, which was maintained for 17 months with continued treatment.